QL-1200186 is anorally activeand selective inhibitor of TYK2. Oral administration of QL-1200186, dose-dependently inhibits interferon-γ (IFNγ) production after interleukin-12 ( IL-12 ) challenge and significantly ameliorates skin lesions in psoriatic mice.